Opal Capital LLC acquired a new stake in shares of Novo Nordisk A/S (NYSE:NVO – Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 200,465 shares of the company’s stock, valued at approximately $10,199,000. Novo Nordisk A/S accounts for approximately 2.6% of Opal Capital LLC’s investment portfolio, making the stock its 7th largest holding.
Several other institutional investors and hedge funds have also bought and sold shares of NVO. Franklin Resources Inc. grew its holdings in Novo Nordisk A/S by 4,190.8% during the third quarter. Franklin Resources Inc. now owns 13,984,789 shares of the company’s stock valued at $776,016,000 after purchasing an additional 13,658,867 shares during the period. Capital International Investors grew its holdings in Novo Nordisk A/S by 52.4% during the third quarter. Capital International Investors now owns 17,713,424 shares of the company’s stock valued at $982,969,000 after purchasing an additional 6,092,192 shares during the period. Boston Partners bought a new position in Novo Nordisk A/S during the third quarter valued at $310,199,000. Bank of Montreal Can grew its holdings in Novo Nordisk A/S by 138.9% during the fourth quarter. Bank of Montreal Can now owns 2,525,827 shares of the company’s stock valued at $128,514,000 after purchasing an additional 1,468,409 shares during the period. Finally, Clear Street Group Inc. bought a new position in Novo Nordisk A/S during the third quarter valued at $56,378,000. 11.54% of the stock is owned by institutional investors.
Novo Nordisk A/S Price Performance
Novo Nordisk A/S stock opened at $43.59 on Wednesday. Novo Nordisk A/S has a one year low of $35.12 and a one year high of $75.78. The business has a fifty day moving average price of $42.55 and a 200-day moving average price of $45.94. The company has a debt-to-equity ratio of 0.59, a current ratio of 0.79 and a quick ratio of 0.56. The firm has a market capitalization of $194.65 billion, a P/E ratio of 10.23, a PEG ratio of 3.92 and a beta of 0.78.
Analyst Upgrades and Downgrades
Several equities analysts have weighed in on the company. Wolfe Research started coverage on Novo Nordisk A/S in a report on Thursday, March 26th. They set a “peer perform” rating for the company. Citigroup reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a report on Tuesday, May 12th. Zacks Research raised Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 10th. Nordea Equity Research lowered Novo Nordisk A/S to a “hold” rating in a report on Tuesday, February 24th. Finally, Weiss Ratings lowered Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday, April 22nd. Four research analysts have rated the stock with a Buy rating, eighteen have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $65.56.
Check Out Our Latest Analysis on NVO
Key Stories Impacting Novo Nordisk A/S
Here are the key news stories impacting Novo Nordisk A/S this week:
- Positive Sentiment: Novo Nordisk said it plans to seek Chinese regulatory approval for its oral Wegovy pill, which could expand its obesity franchise into one of the world’s largest potential markets and strengthen the company’s long-term growth outlook. Reuters: Novo Nordisk to seek regulatory approval for Wegovy pill in China soon, says CEO
- Positive Sentiment: Reports that the company is moving closer to an oral Wegovy filing in China reinforce the view that Novo Nordisk is broadening its weight-loss pipeline beyond injectables, which could help it compete more effectively with Eli Lilly. Article: Novo Nordisk (CPSE:NOVO B) Prepares China Filing For Oral Wegovy Pill
- Neutral Sentiment: Several market-watch and Zacks items indicate that Novo Nordisk remains a heavily followed stock, but they do not add major new fundamental information beyond confirming investor interest and ongoing debate about the outlook. Article: Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know
- Negative Sentiment: A hacking group claimed it stole more than a terabyte of data from Novo Nordisk and attempted to extort $25 million, which raises cybersecurity and reputational concerns that could weigh on sentiment if the breach is confirmed or grows worse. Reuters: Hacking group claims major hack of Novo Nordisk and attempted $25 million extortion
About Novo Nordisk A/S
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.
The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.
Read More
- Five stocks we like better than Novo Nordisk A/S
- Gravity Check: Houston, SpaceX Has a Valuation Problem
- Strategy’s Bitcoin Rally Has a Hidden Engine
- Okta’s AI Moment May Be Bigger Than Investors Realize
- 3 Rate-Ready Stocks for the New Fed Chair’s First Big Test
Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO – Free Report).
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.
-MOODENG.png){kind=small}